PSMAI cut-off value for mortality in men: 680.1 mm2/m2

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years

CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - (ILCN/WCLC)

Cancers, Free Full-Text

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

SARCLISA® (isatuximab-irfc) ICARIA-MM Phase 3 Trial Results

Computed tomographic images at the the middle third lumbar vertebral

ESMO 2021: PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

PSMAI cut-off value for mortality in men: 680.1 mm2/m2

Computed tomographic images at the the middle third lumbar vertebral

PDF) Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy